To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its anti-inflammatory drug Dupixent and newer medicines. ...

Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91 Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and Ayvakit Dupixent sales increased by 26.2% to €4.2 billion, first time above €4 billion in a quarter Vaccines sales decreased by 7.8% to €3.4 billion, from lower influenza sales Research and Development expenses were €1.8 billion, an increase of 4.9% Selling, general and admin ...

Sanofi is set to release its quarterly earnings on October 24, 2025, with an expected EPS of $1.60 and revenue of approximately $12.4 billion.The company's recent success with efdoralprin alfa in the ElevAATe phase II study highlights its commitment to innovation and potential market growth.Financial metrics such as a P/E ratio of 11.66, enterprise value to operating cash flow ratio of 54.30, and a current ratio of 1.27 indicate Sanofi's stable financial position and market valuation.Sanofi (NASDAQ:SNY) is ...

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the Medidata Patient, Data, and Study Experiences, building on both organizations’ shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally. The Medida ...

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care New York – Oct. 23, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research ...

Key Takeaways Sanofi's ElevAATe study showed that efdoralprin alfa met all primary and key secondary endpoints.Efdoralprin alfa achieved higher functional AAT levels versus weekly plasma-derived therapy.The therapy's Q3W and Q4W dosing regimen may enhance convenience for AATD patients.Sanofi (SNY) announced that the phase II ElevAATe study, which evaluated its pipeline candidate, efdoralprin alfa, for the treatment of alpha-1 antitrypsin deficiency (AATD) emphysema, met all primary and key secondary endpoin ...

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...

中国宏观投资环境 - 2025年以来中国继续加大创新投入推动新兴领域投资扩产促进新质生产力形成 [1] - 2025年前三季度大规模设备更新政策成效显著设备购置投资增速始终保持10%以上成为拉动投资增长的关键力量 [7] - 外资企业持续加码投资中国深化全产业链布局对中国经济韧性与市场机遇投下信任票 [1] 汽车行业 - 中国汽车工业向智能化和电动化加速转型吸引海外零部件供应商加大创新投入 [3] - 法雷奥集团2025年第三季度在上海竣工投产新制造基地专注于智能辅助驾驶领域生产智能驾驶摄像头、域控制器、激光雷达等产品 [3] - 中国是世界上最大的汽车市场已成为汽车行业的潮流引领者在电动汽车、智能辅助驾驶、高级辅助驾驶和软件定义汽车等领域走在前列 [5] - 法雷奥集团目标成为中国在汽车行业转型期的首选合作伙伴 [5] 电梯设备行业 - 中国电扶梯保有量全球第一在用电梯超过1100万部其中服役超过15年的电扶梯超过90万台形成庞大更新改造市场 [9] - 奥的斯参与的中国住宅电梯更新项目覆盖34个城市深度融入当地民生工程建设 [9] - 全球人口老龄化、建筑适老化趋势不断加深在中国市场尤为显著 [11] - 中国是奥的斯全球最大的电梯生产基地和全球最大的电梯市场也有最大的数字化服务网络 [11] 医药行业 - 中国在医疗等领域推出扩大开放政策为跨国企业创造更有利的投资环境 [13] - 法国医药企业赛诺菲宣布总投资达10亿欧元约合67亿元人民币的北京生产基地正式启动这是其在华最大单笔投资 [13] - 赛诺菲计划在北京新建一座胰岛素生产基地强化本土药品供应链韧性以更好地服务中国患者 [15] - 中国已成为赛诺菲的关键战略市场2025年恰逢其布局本土化生产30周年 [15]